Jaguar Health, Inc. (NASDAQ:JAGX) shares dipped -22.63% to $0.82 in the premarket session after the report that the Firm has reached an agreement with a secured lender a non-dilutive royalty funding deal.In the agreement, Jaguar will sell a royalty interest to the Lender for an aggregate purchase price of $6 million, entitling the Lender to obtain 2.0x the royalty purchase price of Mytesi and Lechlemer’s potential royalties and others upwards of $6 million.
Jaguar plans to use the proceeds to finance the Company’s research pipeline-related regulatory operations, including ongoing funding patient registration for the cornerstone phase 3 trial of crofelemer for diarrhea prophylaxis in adult cancer patients undergoing targeted therapy launched last October by the wholly-owned subsidiary of the Company, Napo Pharmaceuticals, Inc. (Napo). This $6 million royalty funding deal follows an earlier $6 million royalty transaction with a Lender partner concluded in October 2020.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Moreover, we reported yesterday that Jaguar Health (JAGX) announced the results of the special meeting of Jaguar stockholders held on December 9, 2020.